Together, we keep the world safe. AJ Vaccines A/S is committed to a world free of serious diseases across generations. We develop and manufacture vaccines against serious infectious diseases such as tetanus, diphtheria, tuberculosis, pertussis (whooping cough or 100day cough as more commonly known) and polio. In addition, AJ Vaccines A/S manufactures Tuberculin for screening and diagnosis of high-risk patients for infection with TB, and BCG Culture (Danish Strain 1331) for the standard treatment for intermediate and high-risk non-muscle invasive bladder cancer. AJ Vaccines A/S is a global pharmaceutical company, established in 2017 through the acquisition of SSI, with 100 years of experience in producing high quality vaccines and biologics. Our affiliate office in Malaysia focuses on in-licensing products, such as cholera and influenza vaccines. AJ Vaccines A/S is headquartered in Copenhagen, Denmark and has approximately 600+ employees globally. In line with regulatory guidelines, our LinkedIn page is not intended for discussion about our products. As such, postings or comments that contain product discussions may be removed. Any questions specific to our products should be emailed directly to medicalaffairs@ajvaccines.com. Please be aware that AJ Vaccines A/S and its affiliates work within a highly regulated industry. Therefore, comments that pertain to e.g. legal matters or regulatory issues may be removed. For more information, visit www.ajvaccines.com or follow our hashtag #WeAreAJVaccines.